UPMC Enterprises, the medical technology investment arm of UPMC, has purchased interest in RxAnte, a company that uses analytics to predict how patients will adhere to the medications they’re prescribed.
Read more on Pittsburgh Business Times.
Pittsburgh Business Times: UPMC Enterprises invests in prescription analytics company RxAnte
Related Resources
More Resources
06.12.19
RxEffect Functionality Reflects the Dynamic Nature of Quality Improvement
Blog Post
RxAnte is proud to present “All Quality Improvement Patients” in our patented RxEffect tool. This update enables seamless care coordination by tracking patients over the current calendar year. RxEffect can now be the sole population management tool for medication-related quality improvement initiatives.
05.28.19
RASA Recalls—Assessing the Impact on Member Adherence and CMS Star Ratings Measures
Blog Post
The FDA announced a recall of RASA prescriptions in mid-2018. The drug recall, followed by widespread negative press and medication switching, may have resulted in lower medication adherence among plan members that were prescribed these medications. RxAnte analyzed the impact of the 2018 RASA recalls on Prescription Drug Plan member populations.
05.14.19
Members as Consumers – What it Means for MAPD Plans
Blog Post
The healthcare system once operated without really having to consider what patients or members wanted. We're here to help plans in the shift to patient-centered care.